ReviewPlasma processes and polymers (Print)2022
Cold atmospheric plasma for addressing the COVID-19 pandemic.
Review in Plasma processes and polymers (Print), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Reactive species generated by a cold atmospheric plasma inactivate AAV through oxidative and nitrosative stress.Scientific reports · 2026Article
- Air-fed cold atmospheric plasma device as a safe and effective anti-SARS-CoV-2 air filter.Scientific reports · 2026Article
- In Vitro Safety Study on the Use of Cold Atmospheric Plasma in the Upper Respiratory Tract.Cells · 2024Article
- Spotlight on the impact of viral infections on Hematopoietic Stem Cells (HSCs) with a focus on COVID-19 effects.Cell communication and signaling : CCS · 2023Review
- Inactivation of SARS-CoV-2 on Surfaces by Cold-Plasma-Generated Reactive Species.Bioengineering (Basel, Switzerland) · 2023Article
- Cold atmospheric plasma for addressing the COVID-19 pandemic.Plasma processes and polymers (Print) · 2022Review
- Oral Antiseptics against SARS-CoV-2: A Literature Review.International journal of environmental research and public health · 2022Review
- Cold atmospheric plasma for SARS-CoV-2 inactivation.Physics of fluids (Woodbury, N.Y. : 1994) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has greatly stressed the global community, exposing vulnerabilities in the supply chains for disinfection materials, personal protective equipment, and medical resources worldwide. Disinfection methods based on cold atmospheric plasma (CAP) technologies offer an intriguing solution to many of these challenges because they are easily deployable and do not require resource-constrained consumables or reagents needed for conventional decontamination practices. CAP technologies have shown great promise for a wide range of medical applications from wound healing and cancer treatment to sterilization methods to mitigate airborne and fomite transfer of viruses. This review engages the broader community of scientists and engineers that wish to help the medical community with the ongoing COVID-19 pandemic by establishing methods to utilize broadly applicable CAP technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.